相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
M. -R. Taskinen et al.
DIABETES OBESITY & METABOLISM (2011)
Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study
R. Gomis et al.
DIABETES OBESITY & METABOLISM (2011)
Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial
S. Del Prato et al.
DIABETES OBESITY & METABOLISM (2011)
Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin
U. Graefe-Mody et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes
T. Forst et al.
DIABETIC MEDICINE (2010)
The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans
Stefan Blech et al.
DRUG METABOLISM AND DISPOSITION (2010)
Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects
E. U. Graefe-Mody et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
Ralph A. DeFronzo et al.
DIABETES CARE (2009)
Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients
T. Heise et al.
DIABETES OBESITY & METABOLISM (2009)
Chronic Treatment with the Dipeptidyl Peptidase-4 Inhibitor BI 1356 [(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] Increases Basal Glucagon-Like Peptide-1 and Improves Glycemic Control in Diabetic Rodent Models
Leo Thomas et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Sitagliptin: A novel agent for the management of type 2 diabetes mellitus
David Q. Pham et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2008)
Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers
Samantha Abel et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers
S. Huettner et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors
Leo Thomas et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Gliptins: a new class of oral hypoglycaemic agent
H. Chahal et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2007)
Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response
S Ristic et al.
DIABETES OBESITY & METABOLISM (2005)
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes
A Mari et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year
B Ahrén et al.
DIABETES CARE (2005)
Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes
B Ahrén et al.
DIABETES CARE (2004)
Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
DJ Drucker
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2003)
分享论文
